IP Library Granted Patent US 8,425,897
Granted Patent B2
US 8,425,897 · App. 12/201,905 · Granted Apr 23, 2013

Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,425,897
App. No.
12/201,905
Granted
Apr 23, 2013
Kind
B2
Abstract

The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.

Claims (8)

1. A composition for stimulating an immune response to cancer in a subject, comprising a synergistic combination of:

a) an allogeneic tumor cell line comprising cells that express an antigen of the cancer and that express GM-CSF and which cells have been rendered proliferation-incompetent and

b) an APC activator which is LAG-3.

2. The composition of claim 1 , wherein the cells of said cell line are rendered proliferation-incompetent by irradiation.

3. The composition of claim 1 , wherein said allogeneic cell line is a tumor cell line selected from the group consisting of a prostate tumor line, a non-small cell lung carcinoma line and a pancreatic cancer line.

4. The composition of claim 1 , wherein said LAG-3 is expressed by cells autologous to said subject, or allogeneic to said subject, or are bystander cells.

5. The composition of claim 4 , wherein the cells that express LAG-3 are rendered proliferation-incompetent by irradiation.

6. A method for stimulating an immune response to cancer in a subject which comprises administering to a subject in need of such stimulating an effective amount of the composition of claim 1 .

Assignments (5)
MERGER Recorded Apr 26, 2017
From: CELL GENESYS, INC
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 042117/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2010
From: BIOSANTE PHARMACEUTICALS, INC.
To: IMMUTEP S.A.
Reel/Frame 023890/0585 →
MERGER Recorded Nov 12, 2009
From: CELL GENESYS, INC.
To: BIOSANTE PHARMACEUTICALS, INC.
Reel/Frame 023509/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2009
From: TRIEBEL, FREDERIC
To: IMMUTEP S.A.
Reel/Frame 022167/0816 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2009
From: JOOSS, KARIN; LI, BETTY
To: CELL GENESYS, INC.
Reel/Frame 022167/0880 →